Daniel E. Asarnow

This paper describes a miniprotein inhibitor that neutralizes multiple SARS-CoV-2 variants and protects mice against them when administered post-exposure.

This study shows SARS-CoV-2 nsp1 inhibits translation in bat cells and human cells, revealing its broad activity across mammals.

The paper identifies two European bat MERS-related coronaviruses that use ACE2 as their receptor, revealing a distinct binding mode and host tropism determinants.

The paper isolates two human monoclonal antibodies that broadly neutralize PDCoV variants and identifies their mechanism of action.

The paper identifies 245 putative RNA structural switches in the human transcriptome using a computational and experimental approach, validates one with DMS-MaPseq and cryo-EM, and shows its regulation by trans factors and nonsense-mediated decay.

This study uses deep mutational scanning to assess how mutations in SARS-CoV-2 spike proteins affect ACE2 binding, cell entry, and serum escape, linking these effects to clade growth rates.

This paper develops a stabilization strategy for sarbecovirus fusion machinery vaccines, showing broad reactivity and protection against SARS-CoV-2 variants.

The paper uses deep mutational scanning to explore how chemical perturbations affect ubiquitin's mutational tolerance, revealing sensitization of most positions except two.